早些时候TY - T1的多少可以使用麦当劳多发性硬化诊断标准?乔(P1.234) JF -首页神经-神经学六世- 82 - 10补充SP - P1.234 AU -华莱士Brownlee盟约瑟芬Swanton AU -奥尔加Ciccarelli盟David Miller Y1 - 2014/04/08 UR - //www.ez-admanager.com/content/82/10_Supplement/P1.234.abstract N2 -目的:如何更早可以诊断多发性硬化(MS)患者临床孤立综合征(CIS)使用麦当劳的标准。背景:麦当劳标准允许使用MRI诊断证据女士CIS患者传播在时间和空间。这些标准的高敏感性和特异性clinically-definite女士(CDMS)已在几个CIS军团。如何诊断来得女士并没有被量化。从潜在CIS设计/方法:数据队列与串行临床和MRI评估基线,3个月,发病后1、3和6年了。CDMS根据不易处理的标准定义。麦当劳(mdm)被分配如果女士2001年,2005年或2010年随访期间标准在任何时候都满意。只有一个病人接受了疾病修饰治疗之前开发的探测器。结果:157例患者(平均年龄32.5岁,64%女性)与CIS的平均随访5.98年。 CDMS developed in 71 (45%) cases after a mean of 23.1 months. Using the 2001, 2005 and 2010 MDMS criteria respectively, the mean time to diagnosis for CDMS cases was shortened to 12.0, 10.5 and 6.2 months (p<0.01) and 36 (51%), 40 (56%) and 54 (76%) could be diagnosed with MDMS within 3 months. 32 (45%) CDMS patients fulfilled the 2010 MDMS criteria on the baseline MRI scan. Of the 86 (55%) CIS patients who did not develop CDMS (i.e. had no subsequent clinical episode), 24 (28%), 26 (30%) and 36 (42%) satisfied 2001, 2005 and 2010 MRI criteria for MDMS. Conclusion: Successive iterations of the McDonald criteria allow MS to be diagnosed sooner and more often in CIS patients. A substantial number have radiographic but not clinical conversion to MS in the medium-term (up to 6 years).Disclosure: Dr. Brownlee has nothing to disclose. Dr. Swanton has nothing to disclose. Dr. Ciccarelli has received personal compensation for activities with Bayer Pharmaceuticals Corporation and General Electric. Dr. Miller has received personal compensation for activities with UCL Institute of Neurology, Biogen Idec, GlaxoSmithKline Inc., Novartis, Merck & Co. Inc., Chugai, and Mitsubishi Pharma. Dr. Miller has received personal compensation in an editorial capacity for the Journal of Neurology. Dr. Miller has received research support from Biogen Idec, Schering AG, Apitope, Richmond Pharma, GlaxoSmithKline Inc., and Novartis.Monday, April 28 2014, 3:00 pm-6:30 pm ER -